{"transactions":[{"id":2224334,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T16:38:14.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":8477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":8477,"derivative":{"exercise_price":2.35,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":8477},"source":{"system":"sec-edgar","filing":"0001179110-22-003402","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000117911022003402/edgar.xml","form_type":"4"}},{"id":2441831,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-06T19:26:58.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service."}],"balance_after":6500,"derivative":{"exercise_price":5.45,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001209191-22-002253","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000120919122002253/doc4.xml","form_type":"4"}},{"id":2652168,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"officer":true,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:53:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":48535,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service."}],"balance_after":48535,"derivative":{"exercise_price":26.4,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":48535},"source":{"system":"sec-edgar","filing":"0001140361-21-022781","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000114036121022781/form4.xml","form_type":"4"}},{"id":2652167,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"officer":true,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:53:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":1234,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service."}],"balance_after":1234,"derivative":{"exercise_price":10.25,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":1234},"source":{"system":"sec-edgar","filing":"0001140361-21-022781","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000114036121022781/form4.xml","form_type":"4"}},{"id":2652166,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"officer":true,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:53:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":4830,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the shares underlying this option vest on November 16, 2021, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":4830,"derivative":{"exercise_price":5.9,"expiration_date":"2030-11-15","underlying":"Common Stock","underlying_shares":4830},"source":{"system":"sec-edgar","filing":"0001140361-21-022781","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000114036121022781/form4.xml","form_type":"4"}},{"id":2652165,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"officer":true,"officer_title":"Corporate Controller"}}],"security":"Common Stock","published_at":"2021-06-29T21:53:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":53,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""}],"balance_after":53,"source":{"system":"sec-edgar","filing":"0001140361-21-022781","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000114036121022781/form4.xml","form_type":"4"}}]}